Originally Posted by jimnjana
I'm long on PFE but it does have issues, over all its a gamble that they will manage portfolio of drugs in development and continue to make acquistions that will enhance future pipeline.Jim
This is just the nature of drug companies. Their pipelines are not particularly transparent as often it is not known until very late in the trial sequence what is happening. And ofen not even then- look at all the drugs that have been very expensively pulled because of clinical reports of problems coming in well after they were on the market.
Even if the PFE dividend were reduced it may not effect the share price very much. Drugs are kind of a lottery.